本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
KUALA LUMPUR, Malaysia, Jan. 14, 2025 /PRNewswire/ -- The Malaysian Society for Quality in Health (MSQH), a leading national healthcare accreditation body dedicated to ensuring the highest standards of quality and safety in healthcare services, proudly announces its successful re-certification for the Organisational and Surveyor Training Programme Accreditation (2024–2028) from the International Society for Quality in Health Care External Evaluation Association (IEEA), the accrediting arm of International Society for Quality in Health Care (ISQua). This marks MSQH's fifth consecutive cycle of accreditation, reinforcing its continued global standing in advancing healthcare quality and safety standards. MSQH also holds re-certification for its Standards Accreditation, granted for the period of 2022– 2026, further solidifying the organisation's position as a national and international leader in healthcare quality improvement. ISQua, established in 1985, is an esteemed organisation widely regarded as the "accreditor of accreditors," offering external evaluation for accrediting bodies to meet international benchmarks. This achievement is a testament to MSQH's unwavering commitment to delivering exceptional accreditation services that are recognised internationally, assuring healthcare stakeholders, including patients, insurers, and health ministries, that MSQH-accredited facilities adhere to the highest global standards. Since its founding in 1997, MSQH has been instrumental in promoting continuous improvements in healthcare quality through strategic collaborations with governmental bodies, healthcare organisations and partners. Over the past 25 years, MSQH has spearheaded accreditation programmes and establish the Sixth Edition of Hospital Accreditation Standards, along with standards for Chronic Dialysis Treatment, Dental Clinic, and Medical Clinic. MSQH has accredited 123 hospitals across Malaysia as of December 2024, including both public and private healthcare facilities, as well as dialysis centers and dental clinics. Datuk Dr. Heric Corray, CEO of MSQH, commented, "This re-certification by ISQua signifies the ongoing trust that healthcare facilities place in MSQH's rigorous evaluation process. It reaffirms our role in raising the bar for healthcare quality and safety in Malaysia. We remain committed to empowering healthcare providers through our accreditation programs and are grateful to our clients for their continued support." MSQH will continue to build upon its stellar reputation and lead as a world-class institution, portraying aspiration of MSQH as Educator, Engagement, Enabler, Evaluator and Empowerment in healthcare services. MSQH has also taken concerted efforts to create a voice for prioritisation in patient safety at all levels of healthcare service, from providers to caregivers and families. As we lead to safer and better care for those who matter most must be emphasised at every grassroot level, particularly patients and families. Besides accreditation services, MSQH also offers training and advocacy to healthcare providers across public and private sectors. For more information about MSQH and its initiatives, please visit https://www.msqh.com.my About MSQHMSQH was established in 1997 through a collaborative initiative between the Ministry of Health Malaysia (MOH), the Association of Private Hospitals Malaysia (APHM), and the Malaysian Medical Association (MMA). To date, MSQH is recognised by STANDARDS MALAYSIA and the Ministry of Health Malaysia, as the standards writing organisation and accrediting body for health care facilities and services, both of which are permanent MSQH committee members along with participation from the Academy of Medicine Malaysia (AMM) and the Malaysian Nurses Association (MNA). MSQH continues to play a significant role in fostering, promoting, and supporting continuous improvement efforts for quality and safety in healthcare. MSQH has played a crucial role in the development of standards and accreditation programmes for healthcare facilities and services in the national healthcare agenda since more than 25 years ago. MSQH now has a total of 1,656 memberships and serves as Asia's regional secretariat, constituted by eleven (11) Board members of the Asian Society for Quality in Health Care (ASQua) – www.asquaa.org. All of this legacy is documented and celebrated in the book entitled, "The Journey of MSQH's 25 Years of Continuous Quality Improvement," which is available for viewing and download at www.msqh.com.my. MSQH is taking this opportunity also to educate and promote patients in Malaysia to seek care from MSQH Accredited facilities and service providers. The current list of MSQH accredited healthcare facilities is published in MSQH website www.msqh.com.my. Follow MSQH on Social Media:Facebook: @ OfficialMSQH | Instagram: @ OfficialMSQH | LinkedIn: @ OfficialMSQH A Leading Malaysian Healthcare Accrediting Organisation, Malaysian Society for Quality in Health (MSQH) Earns Global Recognition for its Organisational and Surveyor Training Programme Accreditation
HO CHI MINH CITY, Vietnam, Jan. 14, 2025 /PRNewswire/ -- GlobalTix, Asia's leading ticketing and marketplace distribution platform, has been named "Growth Partner of the Year" by VinWonders, Vietnam's premier operator of world-class theme parks and entertainment destinations. GlobalTix Named VinWonders' Growth Partner of the Year 2024 This recognition highlights GlobalTix's crucial role in boosting VinWonders' international visitor numbers throughout 2024. Through its robust channel management capabilities, GlobalTix has helped VinWonders optimise its distribution strategy and expand its reach into key Asian markets, particularly China and India. "This recognition by VinWonders reflects our commitment to enabling Vietnam's leading attractions to thrive on a global scale," said Moon Le, Commercial Director, GlobalTix Vietnam. "Our robust channel management capabilities enable partners to seamlessly access diverse markets while providing real-time insights and complete data transparency." "Our collaboration with GlobalTix has been instrumental in driving VinWonders' growth in 2024," said Ms. Tran Thu Thuy, Director of E-commerce, VinWonders. "Their channel manager platform and expertise in global distribution have significantly enhanced our ability to attract international visitors, solidifying VinWonders as one of the top destinations for global travellers." Key achievements of the partnership include: Extensive Distribution Reach: Integration with over 12,000 distribution channels, boosting VinWonders' visibility and accessibility. Market Expansion: Successful penetration into major international markets, including China and India, resulting in significant growth in bookings. Future-Focused Collaboration: Positioned to accelerate VinWonders' expansion into additional inbound markets in 2025, leveraging GlobalTix's proven ability to connect attractions with diverse international audiences. GlobalTix's channel management platform has streamlined distribution for VinWonders while enabling resellers to easily connect with Vietnam's top attractions. Resellers looking to offer VinWonders' world-class products can easily access and distribute them through the GlobalTix platform. About GlobalTix GlobalTix is the leading reservation and distribution platform in the Asia-Pacific region focused on providing end to end solutions for attractions, tours, and activities. GlobalTix also enables the same partners to connect tourist activities to travel agents around the globe seamlessly. Founded in 2013, GlobalTix is used by renowned attractions like Mount Faber Leisure Group, Taman Safari Indonesia, Mandai Wildlife Group, National Gallery Singapore, and partners with industry players such as Singapore Airlines and many global online travel agents (OTAs). About VinWonders VinWonders is a world-class recreation brand owned by Vingroup. Retaining the top prestigious choice of every customer in the tourism, resort and entertainment sector in Vietnam, VinWonders creates the "first" experiences for generations of Vietnamese visitors.
MELBOURNE, Australia, Jan. 14, 2025 /PRNewswire/ -- As Australia's retail trading market matures, the focus is shifting beyond regulatory compliance to a broader culture of trader protection and financial security. Mitrade, a global award-winning Contract for Difference (CFD) trading platform, has introduced a million-dollar Excess of Loss Insurance Policy backed by Lloyd's of London to strengthen its trader confidence. With forex and cryptocurrency trading gaining traction in Australia, driven by greater accessibility to technology and growing financial literacy, responsible trading practices have never been more critical. While CFDs offer Australians exposure to global markets with low capital, long-term market sustainability requires more than accessibility—it demands proactive risk management. The CFD broker operates under the Australian Securities and Investments Commission (ASIC), one of the most rigorous regulatory bodies ensuring consumer protection and market transparency. In addition to mandatory safeguards like segregated funds and professional indemnity insurance, Mitrade has secured an Excess of Loss Insurance Policy at no cost to their customers, providing coverage of up to AUD 1,000,000 for qualifying claims in the rare event of company insolvency. "Australia's CFD trading market is built on a strong regulatory framework, continually evolving under ASIC's oversight," said Elven Jong, CEO of Mitrade Australia. "While these standards offer substantial trader protections, our Excess of Loss Insurance provides an additional safeguard beyond compliance. We understand traders seek enhanced fund security and comprehensive education and resources to navigate market complexities. Our commitment reflects the broader industry shift towards proactive trader support, resilience, and risk mitigation." The CFD broker's dedication to trader protection and market transparency has earned industry recognition, including Best Client Fund Security Global 2024 and Best Forex Customer Satisfaction & Happiness Australia 2024 awards. About Mitrade Mitrade is an award-winning CFD trading platform that originated in Melbourne, Australia. Over the years, Mitrade has gained global recognition, offering services through entities regulated by authorities – Australia's ASIC, Cayman Islands' CIMA, Mauritius's FSC, and Cyprus's CySEC. Committed to democratizing global market access, Mitrade connects users to over 700 OTC derivative financial instruments, including indices, forex, commodities, ETFs, and shares. Powered by proprietary AI-driven technology, Mitrade offers fast execution, low spreads, and robust risk management tools. Its multi-device compatibility gives users a seamless trading experience at every stage of their journey. For more information on Mitrade, visit https://www.mitrade.com/.
TOKYO, Jan. 14, 2025 /PRNewswire/ -- Petnow Inc., a pioneering pet tech company, is expanding its footprint in Japan following the app's release in October 2024. Strengthening its presence, Petnow recently received national recognition on Nippon Television's popular show "The Doctor is Jealous Today Too" and is now gearing up to showcase its advanced technology at Interpets 2025, one of the largest and most influential pet industry events in the country. Petnow to Exhibit at Interpets 2025 Held in April at Tokyo Big Sight The Petnow app leverages cutting-edge AI technology to offer a non-invasive biometric identification system for pets, using nose prints for dogs and facial recognition for cats. With its easy-to-use interface and unique solution for pet registration and lost pet recovery, Petnow has already caught the attention of many pet owners across Japan. Interpets, held annually in Tokyo, is Japan's premier international pet fair, gathering industry leaders, businesses, and pet enthusiasts from around the world. Petnow will participate in Interpets 2025 through the Korean pavilion, presenting its AI-driven lost pet recovery system, which promotes community-based search efforts by enabling real-time alerts and collaborative reunions of missing pets. By combining innovative biometric technology with a strong community approach, Petnow is committed to improving pet safety in Japan. Through its participation in Interpets 2025 and growing local partnerships, Petnow is eager to support pet owners in building a safer and more connected environment for their beloved animals. Name: Mr. Jinuk Jung Email: contact@petnow.io Phone No.: +82-10-6439-1139 Website: https://www.petnow.io/ja
O-RAN ALLIANCE Extended Board of Directors has been elected for the upcoming 2-year term Abdurazak Mudesir, Group CTO of Deutsche Telekom, was re-elected as Chair of the Board BONN, Germany, Jan. 14, 2025 /PRNewswire/ -- On December 17, 2024, the O-RAN ALLIANCE General Members Meeting concluded election of its Extended Board of Directors for the upcoming 2-year term. O-RAN ALLIANCE welcomes China Telecom, SoftBank and UScellular as new Board members. Current members of the Board are: Company Director Alternate Director AT&T Yigal Elbaz Brian Daly Boost Mobile Eben Albertyn Jingyi Zhou China Mobile Yuhong Huang Chih-Lin I China Telecom Yue Wang Qingtian Wang Deutsche Telekom Abdurazak Mudesir Petr Ledl KDDI Takuya Sawada Masaaki Koga NTT DOCOMO Takaaki Sato Masafumi Masuda Orange Claire Chauvin Atoosa Hatefi Rakuten Mobile Sharad Sriwastawa Awn Muhammad SoftBank Ryuji Wakikawa Alex Jinsung Choi Telefonica Enrique Blanco Jose Luis Espla TIM Andrea Calvi Marco Caretti UScellular Michael Irizarry Narothum Saxena Verizon Steven Rice Edward Diaz Vodafone Nadia Benabdallah Francisco Martin Abdurazak Mudesir, Group CTO of Deutsche Telekom, was re-elected as Chair of the Board. "With O-RAN ALLIANCE specifications and architecture, operators have the option to deploy Radio Access Networks that are open and secure, and enhanced with intelligent functions to optimize deployments and operations," said Abdurazak Mudesir, Chair of the Board of O-RAN ALLIANCE and Group CTO of Deutsche Telekom. "Guided by operator priorities, O-RAN ALLIANCE remains committed to driving the transformation of the RAN toward openness, intelligence, virtualization, and full interoperability, to enable large-scale deployments in mobile networks." About O-RAN ALLIANCEThe O-RAN ALLIANCE is a world-wide community of mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE's mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations. For more information, please visit www.o-ran.org.
MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.). The presentation will take place this Wednesday, 15 January at 2:15 pm PST (5:15 pm EST / 9:15 am AEDT, 16 January). Participants can register for the webcast at the following link and the webcast presentation can be downloaded here. The webcast will be accessible on demand on the Telix website following the event. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn. Telix Investor Relations AustraliaMs. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com United StatesLisa WilsonIn-Site CommunicationsEmail: lwilson@insitecony.com Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
